glp-1 gip therapy alternatives 2025 Targeting GLP-1, & GCG in Obesity and Type 2 Diabetes Research GLP-1 Agonists For Obesity In

Diabetologia (2006) 49(2):36974

Its lead pipeline drug, CagriSema (semaglutide and cagrilintide), is currently in Phase III development for obesity

All trials revealed cardiovascular safety by establishing non-inferiority

For individuals with BMI above 40 or 50, the difference between 20% and 28% weight loss can be the difference between still being classified as obese and reaching a healthy weight range

Taken orally, these medications, respectively, stimulate the pancreas to produce more insulinthe hormone that helps the bodys cells suck in excess glucose in the bloodstreamand help lower the bodys overall level of blood sugar